Actively Recruiting
Evaluating the Safety and Performance of the Freesolve Resorbable Magnesium Scaffold Compared to the Xience Drug-Eluting Stent in Treating Coronary Artery Lesions
Led by Teleflex · Updated on 2026-08-31
1859
Participants Needed
3
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the Freesolve resorbable magnesium scaffold RMS system compared to the Xience drug-eluting stent DES system in treating patients with up to two new lesions in native coronary arteries. This international, multi-center trial includes up to 1859 subjects randomly assigned in a 21 ratio to receive either the Freesolve RMS or the Xience DES, with the goal of assessing target lesion failure rates at 12 months. Participants will receive either the Freesolve Sirolimus-Eluting Coronary Resorbable Magnesium Scaffold or the Xience Everolimus Eluting Stent. Clinical follow-ups are scheduled at 1, 6, and 12 months after the procedure, and then annually up to 5 years. The study aims to compare the two devices in terms of safety and clinical performance over this timeframe. During the study, participants will undergo clinical evaluations and monitoring at planned intervals to assess outcomes such as procedure success, device success, target lesion and vessel failure, cardiac events, and mortality. Researchers will collect data at hospital discharge and during follow-up visits to measure the primary outcome of target lesion failure at 12 months, along with numerous secondary outcomes up to 5 years. The total participation duration may extend to several years to evaluate long-term effects.
CONDITIONS
Brief Title
Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions
Research Team
B
BIOMAG-III Project Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here